Cosmetic cross-reference

Sucralose

CAS 56038-13-2

Sucralose (CAS 56038-13-2) is a Phase 3 pharmaceutical compound with 2 bioactivity targets and 9 adverse event associations.

SOURCE NLM DailyMed

Label records

0

SOURCE EMBL-EBI ChEMBL

Bioactivity

2

SOURCE DrugCentral

Adverse signals

9

SOURCE IUPHAR/BPS

PubMed IDs

0

SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name

Sucralose

CAS Number

56038-13-2

UNII

96K6UQ3ZD4

InChIKey

BAQAVOSOZGMPRM-QBMZZYIRSA-N

ChEMBL ID

CHEMBL3185084

Molecule Type

Small molecule

Source Match

EMBL-EBI ChEMBL (INCHIKEY)

natural product

SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Clinical Development Phase

Highest clinical development phase rendered from the matched compound identifier rows.

Phase 3

Late-stage clinical development phase from the compound identifier source.

ChEMBL CHEMBL3185084 | Small molecule

SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

This substance also has a cosmetic safety profile →

SOURCE EMBL-EBI ChEMBL 2 bioactivity rows

Bioactivity & Target Interactions

Target-level activity records with assay counts, activity type, and measured value where present.

Target	Activity	Value	Assays	Organism
-	Ki	1250 nM	2	-
-	AC50	39810.7 nM	1	-

SOURCE NLM RxNorm 4 name rows

Drug Names / RxNorm

Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.

Name	RxCUI	Type	Source
SUCRALOSE	1439115	SU	MTHSPL
Sucralose	1439115	SU	MTHSPL
sucralose	1439115	SU	MTHSPL
sucralose	1439115	IN	RXNORM

SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Sucralose used for in pharmaceutical contexts?

Sucralose (CAS 56038-13-2) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Sucralose?

Sucralose has 9 DrugCentral/FAERS adverse event associations. Rendered reaction terms include COVID-19, Device breakage, Diarrhoea, Drug hypersensitivity, Nephrolithiasis. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Sucralose also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for Sucralose with EU status "permitted".

What clinical phase is Sucralose in?

Sucralose is rendered with ChEMBL max phase 3.